Professional Documents
Culture Documents
• 1. Ultrasound
• 2. Maternal serum alpha-fetoprotein or
multiple marker screening
• 3. Amniocentesis
• 4. Chorionic villus sampling (cvs)
• 5. Nuchal translucency
UltraSound
• Obstetric sonography
(ultrasonography) is the
application of medical
ultrasonography to
obstetrics, in which
sonography is used to
visualize the embryo or
foetus in its mother's uterus
(womb). The procedure is
often a standard part of
prenatal care, as it yields a
variety of information
regarding the health of the
Obstetric sonogram of a fetus at 16 weeks. The mother and of the fetus, as
bright white circle center-right is the head, which
faces to the left. Features include the forehead at
well as regarding the
10 o'clock, the left ear toward the center at 7 progress of the pregnancy.
o'clock and the right hand covering the eyes at
9:00.
Maternal serum alpha-fetoprotein
• MSAFP is a screening test that examines
the level of alpha-fetoprotein in the mother's
blood during pregnancy.
• MSAFP may be performed during the 16th
to 18th week
• Alpha- fetoprotein(AFP) is found in both
fetal serum and also amniotic fluid.
• The AFP test is measures high and low
levels of alpha-fetoprotein. The results are
combined with the mother’s age and
ethnicity in order to assess probabilities of
potential genetic disorders.
• High levels of AFP suggestS neural tube
defect such as spina bifida or anencephaly,
defects with the esophagus or a failure of
your baby's abdomen to close.
• Low levels of AFP and abnormal levels of
hCG and estriol may indicate that the
developing baby has Trisomy 21( Down
syndrome), Trisomy 18 (Edwards
Syndrome) or another type of chromosome
abnormality.
Amniocentesis
• Prenatal diagnosis of chromosomal
abnormalities and fetal infections, in
which a small amount of amniotic
fluid, which contains fetal tissues, is
extracted from the amnion or
amniotic sac surrounding a
developing fetus, and the fetal DNA
is examined for genetic
abnormalities.
• Amniocentesis is performed between
the 16th-20th week of pregnancy;
• Possible complications include
infection of the amniotic sac from the
needle, and failure of the puncture to
heal properly, resulting I n leakage or
infection. Serious complications can
result in miscarriage, preterm labor
and delivery, respiratory distress,
postural deformities, fetal trauma and
alloimmunisation (rhesus disease).
risk of amniocentesis-related
miscarriage 1 in 1,600 (0.06)
• One simple drawback is that
administration may be painful.
Chorionic villus sampling (cvs)
• prenatal diagnosis to determine
chromosomal or genetic disorders in the
fetus. It entails getting a sample of the
chorionic villus (placental tissue) and
testing it.
• CVS can be carried out 10-13 weeks after
the last period, earlier than amniocentesis
(which is carried out as early as 14-16
weeks).
• CVS carries a higher risk of harming the
fetus than amniocentesis (miscarriages
occur in around 1 in 100 to 1 in 200 cases
with CVS, versus around 1 in 1,600 with
amniocentesis).
• a risk of miscarriage, there is a risk of
infection and amniotic fluid leakage. The
resulting amniotic fluid leak can develop
into a condition known as oligohydramnios
which is low amniotic fluid level.
• Additionally, there is a risk of CVS causing
digit-reduction defects in the fetus if
performed before 11 weeks (0.07%-0.10%
Newborn Screening
• Purpose to find newborns who
will benefit from early diagnosis
and treatment
• historically, the criteria for
inclusion in a newborn
screening program:
1. Preventable damage
2. Frequency in population
3. Appropriate test
4. Needed to recognize disorder
• Mandated by state law
exception allowed for religious
objection
Screening done for
• Phenylketonuria
• Galactosemia
• Congenital hypothyroidism
• Biotinidase deficiency
• Hemoglobinopathies
• Congenital adrenal hyperplasia
• Hearing
• Disorders detected by tandem mass spectrometry
(example: MCAD)
• Cystic fibrosis
• five lysosomal storage disorders: Pompe, Krabbe,
Niemann-Pick, Gaucher, Fabry (to be implemented)
Newborn screening--tandem mass
spectrometer tests
Amino acid disorders Organic acid disorders
• pku • 3-methylcrotonyl-CoA carboxylase
• maple syrup urine disease deficiency (3MCC)
• tyrosinemia, types I, II and III • 3-hydroxy-3-methylglutaric-CoA lysase
deficiency (HMG)
Urea cycle disorders • glutaric aciduria types I and II (GAI,
• citrullinemia GAII)
• argininosuccinic aciduria • proprionyl CoA carboxylase deficiency
(IVA)
Fatty acid oxidation disorders • isovaleryl CoA dehydrogenase
• carnitine palmitoyl transferase deficiency deficiency
type II (CPT II) • methylmalonic acidemia (MMA)
• long chain 3-hydroxy-coA dehydrogenase • mitochondrial acetoactyl-CoA thiolase
deficiency (LCHAD) deficiency (b-KT)
• medium chain acyl-CoA dehydrogenase • ethylmalonic adipic aciduria
deficiency (MCAD)
• short chain acyl-CoA dehydrogenase
deficiency (SCAD)
• trifunctional protein deficiency (TFPD)
• very long chain acyl-CoA dehydrogenase
deficiency (VLCAD)
Carrier screening
for reproductive decisions
• family history: Tay Sachs, cystic
fibrosis, sickle cell disease,
phenylketonuria
population screening in ethnic groups
• Tay Sachs
• sickle cell disease
• cystic fibrosis, spinal muscular
atrophy
for late onset disorders
• Huntington disease
• breast cancer
• hemochromatosis
Genetic counselling
• possible problem detected
during prenatal testing
• birth of an affected child
• family diagnosis/history of
genetic disorder
• repeated unexplained loss of
pregnancy
• exposure to mutagen
• traditionally nondirective
(contrast with most health care
situations)
• frequently can give estimates
of risk:
– calculated
– empiric data
– test results
Thank You